Resources
About Us
Meticulous Research®—a leading global market research company, published a research report titled, ‘Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology (PCR, Flow Cytometry, NGS) Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor) Sample (Blood, Bone Marrow) – Global Forecast to 2031. According to this latest publication from Meticulous Research®, the global minimal residual disease testing market is projected to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024–2031.
The growth of global minimal residual disease testing market is driven by the growing burden of cancer, extensive application of MRD in blood cancers, the high recurrence rates in some types of cancers, and growing investments and funding for MRD research and testing. Moreover, growth prospects in, the rising adoption of personalized treatments & targeted therapies in the field of oncology, and the growing use of MRD testing in cases of solid tumors are expected to generate market growth opportunities.
Key Players
The key players operating in global minimal residual disease testing market are Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.) and Invivoscribe Inc. (U.S.).
Minimal Residual Disease Testing Market: Future Outlook
The global minimal residual disease testing market is segmented based on offering, technology, application, sample type, and customer type. The report also evaluates industry competitors and analyzes the global minimal residual disease testing market at the regional and country levels.
Among the offerings studied in this report, in 2024, the reagents & assays segment is anticipated to dominate the global minimal residual disease testing market, with a share of 76.7%. The high burden of cancer, repetitive use of assays & reagents, intensive research and development activities by the players in the market leading to launch of new MRD testing, and high use of MRD tests in cancer research and clinical trials are factors contributing to the segment’s dominant position in the minimal residual disease testing market.
Among the technologies studied in this report, in 2024, the flow cytometry segment is anticipated to dominate the global minimal residual disease testing market, with a share of 42.7%. The cost effectiveness of flow cytometry, technology’s ability to simultaneously assess multiple parameters, such as cell size, granularity, and protein expression, and growing advancements are factors contributing to the segment’s dominant position in the minimal residual disease testing market.
Among the applications studied in this report, in 2024, the blood cancers segment is anticipated to dominate the global minimal residual disease testing market. The high burden of blood cancers both economically and on the quality of life, fast progression and high rates of recurrence, high investments in molecular residual disease testing for hematological malignancies, and presence of wide range of tests for blood cancers are factors contributing to the segment’s dominant position in the minimal residual disease testing market.
Among the sample types studied in this report, in 2024, the blood segment is anticipated to dominate the global minimal residual disease testing market. Availability of large number of blood based MRD tests and more patient compliance with blood based MRD tests compared to bone marrow based MRD tests are major factors contributing to the segment’s dominant position in the minimal residual disease testing market.
Among the customer types studied in this report, in 2024, the pharmaceutical & biopharmaceutical companies segment is anticipated to dominate the global minimal residual disease testing market. High investments by pharmaceutical & biopharmaceutical companies in oncology drug development coupled with regulatory authorities promoting the use of MRD testing for clinical trials and high cancer incidence are major factors contributing to the segment’s dominant position in the minimal residual disease testing market.
Geographic Review
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and the Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (UAE, South Africa, Rest of Middle East & Africa). Among the geographies studied in this report, in 2024, North America is anticipated to dominate the global minimal residual disease testing market with a share of 38.8%. High burden of cancer, extensive cancer related R&D activities, high awareness regarding MRD testing and its implementation in routine cancer treatments are major factors contributing to the North America’s dominant position in the minimal residual disease testing market.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6068
Key questions answered in the report-
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
IVD Assay Development Market to be Worth $8.39 Billion by 2031
Read MoreNeurogenomics Market to Reach $4.68 Billion by 2031
Read MoreIndia VNA & PACS Market to Reach $341.6 Million by 2031
Read MoreChina Microarray Market to Be Worth $910.4 Million by 2031
Read MoreChina Neurogenomics Market to Reach $562.1 Million by 2031
Read MoreELISA Market to be Worth $32.69 Billion by 2031
Read MoreDNA Sequencing Market to be Worth $21.30 Billion by 2031
Read MoreOral Care Market to be Worth $58.99 Billion by 2031
Read MoreSpirometer Market to be Worth $1.80 Billion by 2031
Read MorePet Care Market to be Worth $287.96 Billion by 2031
Read MoreRegenerative Medicine Market to be Worth $37.27 Billion by 2031
Read MoreHemostats Market to be Worth $5.32 Billion by 2031
Read MoreBioreactors Market to be Worth $39.96 Billion by 2031
Read MoreProtein Assays Market to be Worth $4.36 Billion by 2031
Read MoreVeterinary API Market to Reach $15.84 Billion by 2031
Read MoreAsia-Pacific NGS Automation Market to be Worth $371 Million by 2031
Read MoreLatin America NGS Market to be Worth $765.2 Million by 2031
Read MoreBiochemical Reagents Market to be Worth $39.61 Billion by 2031
Read MoreMicroarray Kits Market to be Worth $2.51 Billion by 2031
Read MoreAntibody Production Market to Reach $58.35 Billion by 2031
Read MoreMiddle East IVD Market to be Worth $2.15 Billion by 2031
Read MoreSpatial Genomics Market to be Worth $3.23 Billion by 2031
Read MoreAsia-Pacific IVD Market to be Worth $36.02 Billion by 2031
Read MoreEurope NGS Market to be Worth $6.40 Billion by 2030
Read MoreLab Automation Market to be Worth $11.31 Billion by 2031
Read MoreBioinformatics Market to Reach $31.71 Billion by 2031
Read MoreEurope IVD Market to be Worth $39.77 Billion by 2030
Read MoreSequencing Kits Market to be Worth $25.29 Billion by 2031
Read MoreVeterinary API Market to Reach $15.84 Billion by 2031
Read MoreSample Preparation Market to be Worth $12.77 Billion by 2031
Read MoreSurgical Robots Market Worth $25.47 Billion by 2030
Read MoreMedical Coatings Market Worth $3.32 Billion by 2030
Read MoreLiquid Handling Systems Market Worth $6.99 Billion by 2029
Read MoreElectrosurgery Market to be Worth $8.99 Billion by 2031
Read MoreRadiation Dose Management Market Worth $749.1 Million by 2029
Read MoreMolecular Diagnostics Market Worth $46.69 Billion by 2030
Read MoreNewborn Screening Market to be Worth $2.69 Billion by 2031
Read MorePharmacogenomics Market to be Worth $19.5 Billion by 2031
Read MoreDental Practice Management Software Market Worth $ 3.11 Billion by 2029
Read MoreNepal IVD Market Worth $62.7 Million by 2029
Read MorePharmaceutical Contract Packaging Market Worth $42.03 Billion by 2029
Read MoreIndonesia IVD Market Worth $1.11 Billion by 2029
Read MoreMedical Waste Management Market Worth $17.02 billion by 2030
Read MoreEmpty Capsules Market Worth $4.47 Billion by 2029
Read MoreClear Aligners Market to be worth $18.8 Billion by 2030
Read MoreHLA Typing Market Worth $1.9 Billion by 2029
Read MoreReal-world Data Market Worth $1.66 billion by 2029
Read MoreTrack and Trace Solutions Market Worth $27.27 billion by 2029
Read MoreSurface Disinfectant Market Worth $9.52 Billion by 2029
Read MoreElectronic Lab Notebook Market Worth $787.7 million by 2029
Read MoreRapid Diagnostics Market to be Worth $22.65 Billion By 2031
Read MorePlasma Therapy Market Worth $882.5 Million by 2028
Read MorePeripheral Vascular Devices Market Worth $12.02 Billion by 2028
Read MoreBiomaterials Market to Reach 128.7 Billion USD by 2023
Read MoreVaccine Storage Equipment Market Worth $1.83 billion by 2027
Read MorePlasma Fractionation Market Worth $46.9 Billion by 2029
Read MoreHome Healthcare Market to be Worth $514.5 Billion by 2030
Read MoreCardiac Pacemaker Devices Market Worth $4.34 Billion by 2028
Read MoreEuropean Laboratory Informatics Market Worth $1,084.3 Million By 2024
Read MoreCompetent Cells Market Worth 2,318.6 Million USD By 2023
Read MoreCancer Immunotherapy Market to be Worth $267.2 Billion by 2030
Read MoreMultimodal Imaging Market Worth $1.6 Billion By 2024
Read MorePulse Lavage Market to be Worth $661.1 Million by 2030
Read MoreMedical Cooling Systems Market Worth $2.8 Billion By 2024
Read MoreTissue Diagnostics Market Worth $8.52 Billion by 2029
Read MoreEndoscopy Equipment Market Worth $59.8 Billion by 2029
Read MoreAfrican Forensic DNA Testing Market Worth $136.3 Million by 2025
Read MoreClinical Trial Supplies Market to be Worth $5.59 Billion by 2031
Read MoreInfection Control Market Worth $58.2 Billion by 2027
Read MoreSleep Apnea Devices Market Worth $12.9 billion by 2027
Read MoreMedical 3D Printing Market To Reach $983.2 Million By 2020
Read MoreGenomics Market to be Worth $70.52 Billion by 2031
Read MoreAnalytical Standards Market Worth $2.66 Billion By 2027
Read MoreTelehealth Market Worth $539.73 Billion by 2029
Read MoreCell Culture Market Worth $48.63 Billion by 2029
Read MoreAntimicrobial Coatings Market to be Worth $12.41 Billion by 2031
Read MoreFlow Cytometry Market Worth $6.4 Billion by 2027
Read MoreMedical Aesthetics Market Worth $29.43 billion by 2029
Read MoreOligonucleotide Synthesis Market Worth $3.9 Billion by 2025
Read MoreIn Vitro Diagnostics Market to be Worth $116.28 Billion by 2031
Read MoreDental Implants Market Worth $6.52 Billion by 2029
Read MoreActive Implantable Devices Market Worth 24.02 Billion USD By 2022
Read MoreVentilators Market to be Worth $13.23 Billion by 2031
Read MoreDialysis Market to be Worth $36.6 Billion by 2031
Read MorePlasmapheresis Market to be Worth $2.55 Billion by 2030
Read MoreDiabetes Care Devices Market Worth $31.9 Billion by 2028
Read MoreClinical Genomics Market Worth 879.0 Million USD By 2023
Read MoreIVD Quality Control Market to be Worth $2.28 Billion by 2031
Read MoreLaboratory Informatics Market Worth $6.1 Billion by 2030
Read MoreChromatography Data Systems Market to be Worth $1.7 billion by 2030
Read MoreBone Growth Stimulators Market Worth $1.94 Billion by 2030
Read MoreDigital Diabetes Market worth $12.03 billion by 2025
Read MoreTrocars Market Worth $968.5 Million by 2024
Read MoreHealthcare Virtual Assistant Market Worth $1.76 Billion By 2025
Read MoreEurope Hospital Beds Market to be Worth $2.09 Billion by 2030
Read MoreImmunoassay Market Worth $46.49 Billion by 2028
Read MoreHospital Beds Market to Reach $7.09 Billion by 2031
Read MoreUrinalysis Market Worth $2.19 billion by 2027
Read MoreMedical Image Management Market Worth $7.22 billion by 2030
Read MoreBreast Imaging Market Worth $7.08 Billion by 2027
Read MoreVNA & PACS Market to be Worth $6.50 Billion by 2031
Read More